OUR PERSPECTIVES OF GROWTH

INTERIM REPORT
FIRST QUARTER
DEC. 2012–FEB. 2013

GERRESHEIMER

GROUP KEY FIGURES (IFRS)

Financial Year end November 30	Q1 2013	Pro forma[8] Q1 2012	Change in %	Pro forma[8] FY 2012
Results of Operations during Reporting Period in EUR m				
Revenues	296.7	268.8	+10.4	1,219.1
Adjusted EBITDA[1]	46.0	45.1	+2.1	239.9
in % of revenues	15.5	16.8	–	19.7
Adjusted EBITA[2]	25.4	25.3	+0.4	157.9
in % of revenues	8.6	9.4	–	13.0
Results of operations	21.5	18.2	+18.1	131.8
Net income	10.2	7.2	+41.7	68.3
of which attributable to shareholders of Gerresheimer AG	8.6	5.5	+56.4	62.0
of which attributable to non-controlling interests	1.6	1.7	-5.9	6.3
Adjusted net income[3]	13.0	12.2	+7.4	88.3
Net Assets at Reporting Date in EUR m				
Total assets	1,608.0	1,513.5	+6.2	1,555.9
Equity	551.1	556.7	-1.0	538.2
Equity ratio in %	34.3	36.8	–	34.6
Net working capital	221.3	196.5	+12.6	175.2
in % of revenues of the preceding twelve months	17.7	17.4	–	14.4
Capital expenditure	16.6	14.9	+11.4	118.9
Net financial debt	434.6	369.7	+17.6	366.5
Adjusted EBITDA leverage[4]	1.8	1.7	+5.9	1.5
Financial and Liquidity Position during Reporting Period in EUR m				
Cash flow from operating activities	0.1	7.8	-98.7	173.6
Cash flow from investing activities	-67.0	-14.0	>-100	-148.6
thereof cash paid for capital expenditure	-16.6	-14.9	-11.4	-118.9
Free cash flow before financing activities	-66.9	-6.2	>-100	25.0
Employees				
Employees as of the reporting date (total)	11,316	10,284	+10.0	10,952
Stock Data				
Number of shares at reporting date in million	31.4	31.4	–	31.4
Share price[5] at reporting date in EUR	44.13	33.34	+32.4	39.41
Market capitalization at reporting date in EUR m	1,385.7	1,046.9	+32.4	1,237.5
Share price high[5] during reporting period in EUR	44.48	37.21	–	41.34
Share price low[5] during reporting period in EUR	37.60	31.00	–	31.00
Earnings per share in EUR	0.27	0.18	+50.0	1.98
Adjusted earnings per share[6] in EUR	0.36	0.33	+9.1	2.62
Dividend per share in EUR	–	–	–	0.65[7]

[1] Adjusted EBITDA: Earnings before income taxes, net finance expenses, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses.
[2] Adjusted EBITA: Earnings before income taxes, net finance expenses, amortization of fair value adjustments, extraordinary depreciation, restructuring expenses and one-off income and expenses.
[3] Adjusted net income: Consolidated net income (including profit attributable to non-controlling interests) before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and related tax effects.
[4] Adjusted EBITDA leverage: The relation of net financial debt to adjusted EBITDA of the preceding twelve months.
[5] In each case Xetra closing price.
[6] Adjusted net income after non-controlling interests divided by 31.4m shares.
[7] Proposed appropriation of net earnings.
[8] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

SEGMENT KEY FIGURES

› Plastic Systems

The Plastic Systems Division produces complex customer-specific plastic systems for pharmaceuticals, diagnostics and medical technology such as asthma inhalers, insulin pens and lancets, and plastic containers, mainly as primary packaging for pharmaceutics and healthcare.

in EUR m	Q1 2013	Pro forma[3] Q1 2012	Change[4] in %	Pro forma[3] FY 2012
Revenues[1]	110.1	91.6	+20.2	427.2
Adjusted EBITDA[2]	18.5	17.5	+5.9	92.9
in % of revenues	16.8	19.1	–	21.8
Capital expenditure	7.0	6.6	+6.1	43.6

› Moulded Glass

The Moulded Glass Division produces glass primary packaging in a continuous process. The containers are used for pharmaceuticals, cosmetic products and specialty beverages and foods.

in EUR m	Q1 2013	Pro forma[3] Q1 2012	Change[4] in %	Pro forma[3] FY 2012
Revenues[1]	90.8	84.0	+8.1	372.8
Adjusted EBITDA[2]	16.3	16.3	0.0	81.6
in % of revenues	18.0	19.4	–	21.9
Capital expenditure	5.4	3.7	+45.9	40.7

› Tubular Glass

The Tubular Glass Division initially produces high-quality glass tubes. These tubes are subsequently converted into ampoules, cartridges, vials or syringe systems.

in EUR m	Q1 2013	Pro forma[3] Q1 2012	Change[4] in %	Pro forma[3] FY 2012
Revenues[1]	77.8	73.7	+5.5	333.8
Adjusted EBITDA[2]	14.2	13.8	+2.7	70.2
in % of revenues	18.2	18.7	–	21.0
Capital expenditure	4.1	4.1	0.0	32.6

› Life Science Research

The product spectrum of the Life Science Research Division consists of laboratory glassware for research, development and analytics.

in EUR m	Q1 2013	Pro forma[3] Q1 2012	Change[4] in %	Pro forma[3] FY 2012
Revenues[1]	21.5	23.0	-6.4	99.6
Adjusted EBITDA[2]	2.5	2.5	-0.8	13.5
in % of revenues	11.7	11.1	–	13.6
Capital expenditure	0.1	0.5	-80.0	1.6

[1] Revenues by segment include intercompany revenues.
[2] Adjusted EBITDA: Earnings before income taxes, net finance expenses, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses.
[3] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.
[4] The change has been calculated on a EUR k basis.

KEY FACTS
FIRST QUARTER 2013

- Revenues increase by 10.4% to EUR 296.7m
- Adjusted EBITDA margin of 15.5% attained (Q1 2012: 16.8%)
- Net income grows by 41.7% to EUR 10.2m (Q1 2012: EUR 7.2m)
- Adjusted earnings per share increase to EUR 0.36 (Q1 2012: EUR 0.33)
- Confirmation of outlook for the financial year 2013
- Successful acquisition and integration of the Indian company Triveni in the area of pharmaceutical plastic packaging

Contents

GERRESHEIMER ON THE CAPITAL MARKETS

GOOD START TO THE YEAR ON THE MARKETS

The stock markets began financial year 2013 with a good upward price trend. Generally attractive share prices combined with relatively low interest rates on fixed income alternatives gave good reason to invest in shares. Alongside this, the expectation of rising inflation rates persists, especially in the USA and the euro area, and this is also likely to have boosted demand for equity investments. In this favorable climate, the MDAX index likewise rose in the first quarter of 2013. The index was up 14.5% as of the February 28, 2013 reporting date.

MARKED RISE IN THE GERRESHEIMER SHARE PRICE

Gerresheimer shares (ISIN: DE000A0LD6E6) sustained their upward trend through the first quarter of 2013. After a consolidation at the start of the first quarter, publication of the strong figures for financial year 2012 on February 14, 2013 gave new buoyancy to the share price. Shortly afterwards, on February 20, 2013, the share price marked an all-time high at EUR 44.48. At that point in time, the share price gain since the start of the financial year amounted to 12.9%. Overall, Gerresheimer shares closed the first quarter on February 28, 2013 with a share price of EUR 44.13, corresponding to a gain of 12.0%.

The Company's market capitalization was EUR 1,385.7m at the end of the first quarter on February 28, 2013. Based on the German Stock Exchange index ranking, Gerresheimer shares consequently occupied 27th place in the MDAX index (prior year quarter: 29th). In terms of stock exchange turnover, the Company's shares occupied 32nd place at the reporting date, compared with 39th place at the end of the prior year. Gerresheimer shares thus improved their ranking on both key positioning criteria in the MDAX index.

Gerresheimer shares versus MDAX (rebased)

Index: November 30, 2012 = 100%



BUY RECOMMENDATION FROM MAJORITY OF ANALYSTS

Gerresheimer shares were covered by 16 bank analysts as of the end of the first quarter of 2013. As before, buy recommendations were substantially in the majority. The charts that follow provide an overview of the banks covering Gerresheimer at the end of the first quarter together with their recommendations.

Analyst coverage

Berenberg Bank	equinet Bank	LBBW
Cheuvreux	Hauck & Aufhäuser	MainFirst
Commerzbank	HSBC	Metzler
Credit Suisse	Jefferies	National-Bank
Deutsche Bank	J.P. Morgan Cazenove	
DZ Bank	Kepler	

Overview of analyst recommendations (as of February 28, 2013)

Number (prior year)



Gerresheimer shares: Key data

	Q1 2013	Pro forma[4] Q1 2012	Pro forma[4] FY 2012
Number of shares at reporting date in million	31.4	31.4	31.4
Share price[1] at reporting date in EUR	44.13	33.34	39.41
Market capitalization at reporting date in EUR m	1,385.7	1,046.9	1,237.5
Share price high[1] during reporting period in EUR	44.48	37.21	41.34
Share price low[1] during reporting period in EUR	37.60	31.00	31.00
Earnings per share in EUR	0.27	0.18	1.98
Adjusted earnings per share[2] in EUR	0.36	0.33	2.62
Dividend per share in EUR	–	–	0.65[3]

[1] Xetra closing price.
[2] Adjusted net income after non-controlling interests divided by 31.4m shares.
[3] Proposed appropriation of net earnings.
[4] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Share reference data

ISIN	DE000A0LD6E6
WKN	A0LD6E
Bloomberg symbol	GXI
Reuters symbol	GXIG.DE
Index membership	MDAX, CDAX, HDAX, Prime All Share, Classic All Share, EURO STOXX TMI, Russell Global Small Cap Growth Index, and further sector and size indexes
Listings	Berlin, Duesseldorf, Frankfurt (Xetra and floor trading), Hamburg, Hanover, Munich, Stuttgart

GERRESHEIMER BOND PRICE: STRONG AT HIGH LEVEL

After the very healthy performance of the Gerresheimer bond price (ISIN: XS0626028566) in financial year 2012, the bond price held its own at a high level in the first quarter of 2013. At first stable through the first half of the first quarter of 2013, the bond price then traced a slight downward trend in line with the generally weaker overall market. At 111.0%, the bond price closed back at a higher level as of the February 28, 2013 reporting date. The bond price is likely to have continued to benefit now that policies for tackling the tight financial situation in various euro area member states have become more specific and on publication of Gerresheimer AG's full-year figures on February 14, 2013. Based on the closing price at the February 28, 2013 reporting date, the effective annual interest rate (yield to maturity) amounted to 2.7% p.a. The bond can be traded in Frankfurt (on Xetra and in floor trading) as well as on regional exchanges in Germany.

Gerresheimer AG corporate bond: Price performance

Market price November 30, 2012: 111.5%



Bond reference data

ISIN	XS0626028566
WKN	A1H3VP
Issuer	Gerresheimer AG
Principal amount	EUR 300m
Coupon/coupon date	5% p.a./May 19
Maturity date	May 19, 2018
Bond price[1] at reporting date	111.0%
Effective annual interest rate (yield to maturity)[2] at reporting date	2.7% p.a.
Bond rating at reporting date	Standard & Poor's: BBB-, stable outlook Moody's: Ba1, stable outlook
Corporate rating at reporting date	Standard & Poor's: BBB-, stable outlook Moody's: Ba1, stable outlook
Denomination	EUR 1,000.00 par value
Listings	Berlin, Duesseldorf, Frankfurt (Xetra and floor trading), Hamburg, Hanover, Munich, Stuttgart

[1] Closing price, Stuttgart Stock Exchange.
[2] Based on the closing price on Stuttgart Stock Exchange.

INTERIM GROUP MANAGEMENT REPORT DECEMBER 2012–FEBRUARY 2013

BUSINESS ENVIRONMENT

The first quarter of 2013 saw a continuation of the recessionary trend in the eurozone, albeit amid the first signs of progress on the necessary adjustments. In Germany, export growth slowed noticeably, due primarily to weaker demand from the euro area in the second half of 2012. Overall, however, the German economy remains highly competitive and in good shape. In its analysis published at the beginning of 2013, the Federal Ministry of Economics and Technology[1] therefore predicts that the German economy will make a positive start to 2013 and quickly overcome the temporary weakness.

At the regional level, economic performance varied considerably in the first quarter of 2013. While the US economy is likely to have grown by around 2.0% in the first three months according to forecasts from experts, the pace of economic expansion in the eurozone is predicted to have dropped by around 0.9%. The situation was somewhat better in Germany, where the signs continued to point to growth. Gross domestic product (GDP) is forecast to rise by around 0.2% in the first quarter of 2013. The emerging market economies remained much more dynamic. Notably in China and India, GDP is forecast to grow by approximately 8.1% and 5.3% respectively in the first quarter of 2013. By contrast, GDP in Brazil is expected to rise by 2.4% and in Russia by 2.0% in the first quarter of 2013.

In the first quarter of 2013 the market for pharmaceutical primary packaging and drug delivery systems was again driven by key trends such as the population's increasing life expectancy, which is associated with more extensive medical care requirements. The continuously rising number of patients suffering from chronic diseases such as diabetes or asthma are profiting from therapies that are made possible by insulin pens, inhalers and other drug delivery devices. Demand is also being driven by the increasing number of patients who opt for self-medication rather than hospital or out-patient treatment. The more comprehensive range of generic drugs on the market which are gradually replacing patent-protected medications is also a source of potential revenue for us because the number of (packaging) units sold tends to increase considerably.

There was also further growth in demand in the more cyclical business of cosmetic products in the first quarter of 2013. It is to be observed that glass packaging with a perceivably high value is much in demand. Design and additional finishing techniques of the glass containers are thereby of crucial importance. Demand in the market for life science research products was impacted by destocking and budget restrictions in the US.

BUSINESS DEVELOPMENT

The Gerresheimer Group decided on the early adoption of IAS 19 Employee Benefits (amended in 2011) from December 1, 2012. As a result, the comparative prior year figures in this interim report have been restated. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

The Gerresheimer Group generated revenues of EUR 296.7m in the first quarter of 2013, an increase of 10.4% or EUR 27.9m compared with the prior year quarter. This was due primarily to strong organic growth in the Plastic Systems Division, which also benefited from the revenues generated by Triveni Polymers Private Ltd. (Triveni), the company acquired in December 2012. The Moulded Glass and Tubular Glass Divisions also contributed to the pleasing revenue growth. Compared to the prior year quarter it must be taken into account, that the acquired Indian Moulded Glass company Neutral Glass was included in the group financial statements starting with the second quarter 2012. Adjusted for exchange rate effects, the Gerresheimer Group increased revenues by 11.1% in the first quarter of 2013. Adjusted for consolidation effects (initial consolidation of Triveni and Neutral Glass as well as the deconsolidation of Kimble Bomex Glass) of about EUR 5.8m, revenue increased by 8.8%.

In the first quarter 2013 adjusted EBITDA increased by 2.1% to EUR 46.0m. The adjusted EBITDA margin was 15.5% in the first quarter of 2013 and thereby as expected down on the prior year margin of 16.8%.

The results of operations improved, reaching EUR 21.5m after EUR 18.2m of the prior year quarter. Besides the improvement in operating income, this is also attributable to the EUR 2.5m decline in one-off expenses. At EUR 10.2m, net income after income taxes in the first quarter of 2013 was EUR 3.0m up on the prior year figure of EUR 7.2m, due not least to the improvement in net finance expenses.

[1] Federal Ministry of Economics and Technology; www.bmwi.de

The net asset position remains very solid. The equity ratio is on the level of November 30, 2012. It has to be taken into account, that the equity of the financial year 2012 has been adjusted because of the first time application of the new standard governing pension obligations (IAS 19 amended). As a result, the equity ratio declined from 37.2% to 34.6%. This issue is explained in detail in the notes to this interim report. Non-current assets were fully covered by equity and non-current liabilities. Leverage–the ratio of interest-bearing net financial debt to adjusted EBITDA in the last twelve months of 1.8–was above the figure at the end of the financial year. As at November 30, 2012 leverage was at 1.5. The primary reason for this increase is the acquisition of the Indian company Triveni.

On December 17, 2012, the sale and purchase agreement was signed for the majority interest in the Indian company Triveni, New Delhi. Triveni produces plastic pharmaceutical packaging. Gerresheimer has acquired 75% of the company's shares. The transaction was completed on December 20, 2012 and the company has been included in the consolidated financial statements of Gerresheimer AG since that date. In addition, from April 1, 2016, Gerresheimer has the possibility to purchase the remaining 25% stake by exercising its option to buy (call option). Likewise, from this date onwards, the seller can tender the remaining 25% stake to Gerresheimer by exercising its option to sell (put option). In the financial year from April 1, 2011 through March 31, 2012, Triveni generated revenues of around INR 1.3bn (around EUR 20m) and employed more than 300 people.

As in prior years, external factors such as exchange rate fluctuations or the development of energy and commodity prices had little influence on the results of operations of the Gerresheimer Group in the reporting period. Fluctuations in the US dollar/ euro exchange rate do not have a material effect on the development of the Group's result and essentially only led to translation effects due to our production sites in the US with mainly North American pharma customers and financial debt in US dollars. Price fluctuations for raw materials and energy are substantially equalized by contractually agreed price escalation clauses, hedging transactions, productivity and price increases

REVENUE DEVELOPMENT

The Gerresheimer Group generated revenues of EUR 296.7m in the first quarter of 2013. This year-on-year increase of EUR 27.9m or 10.4% is due primarily to strong organic growth in the Plastic Systems Division, which also benefited from the revenues generated by Triveni since its acquisition in December 2012. The Moulded Glass and Tubular Glass Divisions also contributed to the revenue growth. Adjusted for exchange rate effects, the Gerresheimer Group increased revenues by 11.1% in the first quarter of 2013.

in EUR m	**Q1 2013**	Q1 2012	Change in %
Revenues			
Plastic Systems	110.1	91.6	20.2
Moulded Glass	90.8	84.0	8.1
Tubular Glass	77.8	73.7	5.5
Life Science Research	21.5	23.0	-6.4
Sub-total	**300.2**	**272.3**	**10.2**
Intragroup revenues	-3.5	-3.5	0.0
Total Revenues	**296.7**	**268.8**	**10.4**

Revenues in the Plastic Systems Division increased by 20.2% or EUR 18.5m to EUR 110.1m in the first quarter of 2013. Adjusted for exchange rate effects, revenues grew by 23.0%. Revenues were up in both the primary packaging and the drug delivery devices businesses. The strongest revenue growth in the first quarter of 2013 was achieved in the engineering and tooling business. Triveni, which has been consolidated since December 20, 2012, also made a pro-rata contribution to this positive trend in revenues.

Our Moulded Glass Division generated revenues of EUR 90.8m in the first quarter of 2013, an increase of 8.1% compared with the prior year period. On a like-for-like exchange rate basis, the revenues increased by 8.2%. It is important to bear in mind that the comparative prior year quarter figures did not include our Indian company Neutral Glass. Adjusted for the pro-rata revenues of Neutral Glass, revenues in the Moulded Glass Division grew by 4.1% after adjustments for exchange rate effects and thereby met our expectations. While the pharma business stagnated, the cosmetics business once again showed pleasing rates of growth.

At EUR 77.8m, revenues in the Tubular Glass Division were up 5.5% on the prior year figure of EUR 73.7m. On a like-for-like exchange rate basis, revenues in the Tubular Glass Division rose by 5.1% year on year. This revenue growth is essentially attributable to sustained high demand in the RTF®-syringe business, although revenues from vials and cartridges also showed pleasing growth compared with the prior year quarter.

The Life Science Research Division recorded a 6.4% decline in revenues in the first quarter of 2013 (6.7% after adjustment for exchange rate effects). It should be taken into account that the prior year quarter included the revenues of Kimble Bomex Glass, which was sold in September 2012. After adjustment for this effect, revenues were 0.9% lower year on year. This trend was due to destocking as well as customers' reluctance to place orders because of reduced research budgets in the US.

RESULTS OF OPERATIONS

The Gerresheimer Group generated an adjusted EBITDA of EUR 46.0m in the first quarter of 2013, an increase of 2.1% on the prior year quarter. The adjusted EBITDA margin was 15.5% in the first quarter of 2013, below the adjusted EBITDA margin of 16.8% in the comparative period. The main cause for this development was the decrease in margins in the Plastic Systems Division. This was due, firstly, to price reductions with two customers. Secondly, there was a substantial increase in tools two revenues, where margins are generally lower than in the parts business.

			Margin in%	
in EUR m	**Q1 2013**	Pro forma[1] Q1 2012	Q1 2013	Pro forma[1] Q1 2012
Adjusted EBITDA				
Plastic Systems	18.5	17.5	16.8	19.1
Moulded Glass	16.3	16.3	18.0	19.4
Tubular Glass	14.2	13.8	18.2	18.7
Life Science Research	2.5	2.5	11.7	11.1
Sub-total	**51.5**	**50.1**	**–**	**–**
Head office/ Consolidation	-5.5	-5.0	–	–
Total adjusted EBITDA	**46.0**	**45.1**	**15.5**	**16.8**

[1] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Adjusted EBITDA in the Plastic Systems Division increased by 5.9% to EUR 18.5m compared with the prior year quarter. The adjusted EBITDA margin in the first quarter of 2013 was 16.8%, as expected, compared with 19.1% in the prior year quarter. A significant portion of the revenue growth related to higher engineering and tools revenues with what are–even for this business–exceptionally low margins. Besides product ramp-up costs, as expected margins were brought down by price reductions with two major customers.

Adjusted EBITDA in the Moulded Glass Division was EUR 16.3m, on a par with the strong prior year quarter. As already communicated during our Investor and Analyst Conference on February 14, 2013 the division had a weak start in December. Consequently capacity adjustments for inventory optimization were temporarily implemented in December and January. In February revenues could be increased due to destocking despite almost maximum capacity utilization. The adjusted EBITDA margin was 18.0% in the first quarter of 2013, down as expected on the 19.4% of the prior year quarter.

Adjusted EBITDA in the Tubular Glass Division was EUR 14.2m in the first quarter of 2013, compared with EUR 13.8m in the same period of the prior year. The adjusted EBITDA margin remained at 18.2% after 18.7% in the prior year period. Increased personnel costs due to the training of new employees for the planned expansion of syringe production as well as quality costs in syringe assembly that are still too high affected the margin.

Adjusted EBITDA in the Life Science Research Division of EUR 2.5m was on the same level as the first quarter of 2012. In the first quarter of 2013, the adjusted EBITDA margin was 11.7%, compared with 11.1% in the first quarter of 2012. This marginal increase is mainly due to the already described fall in revenues that is mainly a consequence of the sale of the Kimble Bomex Glass entity in September 2012.

The following table shows the reconciliation of adjusted EBITDA to the net income for the period:

in EUR m	Q1 2013	Pro forma[4] Q1 2012	Change
Adjusted EBITDA	**46.0**	**45.1**	**0.9**
One-off income/ expense[1]	0.1	2.6	2.5
EBITDA	**45.9**	**42.5**	**3.4**
Amortization of fair value adjustments[2]	3.8	4.5	0.7
Depreciation and amortization	20.6	19.8	-0.8
Results of operations	**21.5**	**18.2**	**3.3**
Net finance expenses[3]	-6.4	-7.7	1.3
Income taxes	-4.9	-3.3	-1.6
Net income	**10.2**	**7.2**	**3.0**
Attributable to non-controlling interests	1.6	1.7	-0.1
Attributable to equity holders of the parent	**8.6**	**5.5**	**3.1**

[1] The item comprises one-off items which cannot be taken as an indicator of ongoing business operations. These include, for example, various expenses for reorganization and structure changes which are not reportable as "restructuring expenses" according to IFRS.

[2] Amortization of fair value adjustments relates to the assets identified at fair value in connection with the acquisitions of Gerresheimer Vaerloese in December 2005, Gerresheimer Regensburg in January 2007, the pharma glass business of Comar Inc., USA, in March 2007, the new formation of the Kimble Chase joint venture in July 2007 as well as the acquisitions of Gerresheimer Zaragoza and Gerresheimer Sao Paulo in January 2008, the acquisition of Vedat in March 2011 and the acquisition of Neutral Glass in April 2012.

[3] Net finance expenses comprises interest income and expenses in relation to the net financial debt of the Gerresheimer Group. In addition, interest expenses for pension provisions less expected income from fund assets and currency effects from financing activities as well as valuation effects from related derivative financial instruments are included.

[4] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from restatement can be found in the notes to this interim report.

Adjusted EBITDA is reconciled to EBITDA by deducting one-off income and expenses. The balance of one-off income and expenses in the first quarter of 2013 relates in its entirety to expenditure in connection with acquisition projects. Compared with the prior year quarter the one-off expenses decreased by EUR 2.5m. There was a substantial decrease in amortization of fair value adjustments. This is firstly attributable to the fact that amortization on earlier acquisitions is decreasing or items assumed at acquisition being fully amortized. Secondly, purchase price allocation in connection with the new acquisition of Neutral Glass resulted in little additional amortization on fair value adjustments. Depreciation and amortization, in contrast, went up by EUR 0.8m compared with the prior year quarter. This is mainly a result of the high level of capital expenditure in the prior year. This capital expenditure is now leading to higher depreciation and amortization. The results of operations consequently improved compared with the prior year quarter by EUR 3.3m to EUR 21.5m.

Net finance expenses for the first quarter of 2013 were EUR 1.3m down on the first quarter of 2012. This is mainly attributable to the measurement of foreign currency loans. The tax ratio is 32.4% in the first quarter 2013 after 31.4% in the prior year quarter. Net income after income taxes for the first quarter of 2013 totaled EUR 10.2m, EUR 3.0m higher than net income after income taxes of the comparative prior year period. Deducting net income attributable to non-controlling interests, net income attributable to equity holders of the parent for the three months ending February 28, 2013 was EUR 8.6m (prior year: EUR 5.5m).

The following table shows the reconciliation of net income to adjusted net income after non-controlling interests:

in EUR m	Q1 2013	Pro forma[1] Q1 2012	Change
Net income	**10.2**	**7.2**	**3.0**
Amortization of fair value adjustments	3.8	4.5	-0.7
tax effect thereon	-1.1	-1.4	0.3
One-off income/expense	0.1	2.6	-2.5
tax effect thereon	0.0	-0.7	0.7
Adjusted income	**13.0**	**12.2**	**0.8**
Attributable to non-controlling interests	1.6	1.7	-0.1
Adjusted income after non-controlling interests	**11.4**	**10.5**	**0.9**

[1] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from restatement can be found in the notes to this interim report.

NET ASSETS

	Feb. 28, 2013		Pro forma[1] Nov. 30, 2012	
	in EUR m	in %	in EUR m	in %
Assets				
Non-current assets	1,131.4	70.4	1,071.4	68.9
Current assets	476.6	29.6	484.5	31.1
Total assets	**1,608.0**	**100.0**	**1,555.9**	**100.0**
Equity and Liabilities				
Equity and non-controlling interests	551.1	34.3	538.2	34.6
Non-current liabilities	668.8	41.6	653.5	42.0
Current liabilities	388.1	24.1	364.2	23.4
Total equity and liabilities	**1,608.0**	**100.0**	**1,555.9**	**100.0**
Net financial debt	**434.6**	**27.0**	**366.5**	**23.6**
Net working capital	**221.3**	**13.8**	**175.2**	**11.3**

[1] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from restatement can be found in the notes to this interim report.

At February 28, 2013, the Gerresheimer Group's total assets stood at EUR 1,608.0m, an increase of EUR 52.1m compared with November 30, 2012. This is mainly a result of the initial consolidation of Triveni and the recognition of preliminary goodwill of EUR 62.5m in non-current assets. There were no significant changes in balance sheet structure.

Non-current assets, at EUR 1,131.4m, likewise exceeded the November 30, 2012 figure for the reasons mentioned. They accounted for 70.4% of total assets at February 28, 2013, compared with 68.9% at November 30, 2012.

Current assets of EUR 476.6m were slightly below the prior year level. This was primarily caused by lower cash and cash equivalents which decreased by EUR 24.5m. This development was in part compensated by the seasonal increase in inventories of EUR 11.6m as well as by the initial consolidation of Triveni (EUR 8.8m).

The Gerresheimer Group's consolidated equity, including non-controlling interests, increased from EUR 538.2m to EUR 551.1m at February 28, 2013. This is especially attributable to the positive net income. It has to be taken into account that Gerresheimer elected early application of IAS 19 (amended) with effect from December 1, 2012. The adjustment to pension provisions in accordance with the revised standard resulted in a EUR 41.9m charge to equity as of December 1, 2012. The equity ratio decreased from 37.2% as at November 30, 2012 to 34.6% as at November 30, 2012 pro forma mainly as a result of this special item.

Likewise, non-current liabilities increased to EUR 668.8m at the end of February 2013, compared with EUR 653.5m at the end of November 2012. This is primarily attributable to an agreement made in connection with the acquisition of Triveni. As a result of this agreement, from April 1, 2016 onwards, Gerresheimer may be obliged to purchase shares, which the other shareholders hold in this company. The obligation arising from this agreement has been disclosed in non-current financial liabilities. Equity and non-current liabilities now provide 108% coverage of non-current assets.

Current liabilities also went up by EUR 23.9m to EUR 388.1m. This mainly reflects drawings on the revolving credit facility, which was primarily used to pay the purchase price for the majority shareholding in Triveni.

The **net financial debt** developed as follows:

in EUR m	Feb. 28, 2013	Pro forma[3] Nov. 30, 2012	Pro forma[3] Feb. 29, 2012
Financial debt			
Senior facilities			
Term Loan[1]	134.4	135.8	154.4
Revolving Credit Facility	45.0	0.0	0.0
Total senior facilities	**179.4**	**135.8**	**154.4**
Senior Notes–Euro Bond	300.0	300.0	300.0
Local borrowings[1]	10.6	10.0	15.1
Finance lease liabilities	6.2	6.8	8.9
Total financial debt	**496.2**	**452.6**	**478.4**
Cash and cash equivalents	61.6	86.1	108.7
Net financial debt	**434.6**	**366.5**	**369.7**
Adjusted LTM EBITDA[2]	**240.8**	**239.9**	**220.6**
Adjusted EBITDA Leverage	**1.8**	**1.5**	**1.7**

[1] For the translation of US dollar loans to EUR the following exchange rates were used: As at November 30, 2012: EUR 1.00/USD 1.2986; as at February 29, 2012: EUR 1.00/USD 1.3443; as at February 28, 2013: EUR 1.00/USD 1.3129.
[2] Cumulated adjusted EBITDA of the last twelve months.
[3] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from restatement can be found in the notes to this interim report.

Net financial debt increased by EUR 68.1m to EUR 434.6m as at February 28, 2013 (November 30, 2012: EUR 366.5m). This is essentially attributable to payment of the purchase price for the acquisition of Triveni. Adjusted EBITDA leverage (the ratio of net financial debt to adjusted EBITDA in the last twelve months) of 1.8 was above the level of 1.5 recorded at November 30, 2012.

Long-term senior credit facilities as at February 28, 2013 comprise redeemable loans with an initial principal amount of EUR 150.0m (drawn entirely in USD) and a EUR 250.0m revolving credit facility. Drawings on the revolving credit facility totaled EUR 45.0m as at February 28, 2013. Gerresheimer has the remaining amount at its disposal for further capital expenditure, acquisitions and other operational requirements.

The Gerresheimer Group's net working capital was EUR 221.3m at February 28, 2013, an increase of EUR 46.1m compared with November 30, 2012.

in EUR m	**Feb. 28, 2013**	Nov.30, 2012	Feb. 29, 2012
Inventories	200.6	189.0	180.6
Trade receivables	188.0	179.4	159.4
Trade payables	129.3	154.3	110.6
Prepayments	38.0	38.9	32.9
Net working capital	**221.3**	**175.2**	**196.5**

The increase in net working capital in comparison to the prior year partly relates to the newly acquired Indian company, Triveni (EUR 6.2m), which was not included in the prior year. On the other hand, trade payables decreased considerably due to reporting date-related issues. When comparing the net working capital figure of the first quarter of 2013 to the prior year quarter value, one must also consider the Indian company Neutral Glass with net working capital of EUR 5.3m, which was not yet included in the prior year quarter.

As a proportion of revenues in the past twelve months, the average net working capital increased from 18.1% in the prior year to 18.2% in the period under review.

CASH FLOW STATEMENT (ABBREVIATED VERSION)

in EUR m	**Dec. 1, 2012– Feb. 28, 2013**	Dec. 1, 2011– Feb. 29, 2012
Cash flow from operating activities	0.1	7.8
Cash flow from investing activities	-67.0	-14.0
Cash flow from financing activities	42.6	-17.6
Changes in cash and cash equivalents	-24.3	-23.8
Effect of exchange rate changes on cash and cash equivalents	-0.2	1.1
Cash and cash equivalents at the beginning of the period	86.1	131.4
Cash and cash equivalents at the end of the period	61.6	108.7

Operating activities generated a cash inflow of EUR 0.1m in the first three months of 2013 (Q1 2012: cash inflow of EUR 7.8m). The negative development mainly results from the increase in net working capital.

The EUR 67.0m net cash outflow from investing activities is significantly larger than the EUR 14.0m prior year figure. Besides investments in property, plant and equipment and intangible assets, the acquisition of Triveni in December 2012 is also included in the first quarter of 2013 figure.

The net cash inflow from financing activities amounted to EUR 42.6m (Q1 2012: cash outflow of EUR 17.6m) and was essentially attributable to the EUR 45.0m drawings on the revolving credit facility.

CAPITAL EXPENDITURE

in EUR m	**Q1 2013**	Q1 2012	Change in %
Plastic Systems	7.0	6.6	6.1
Moulded Glass	5.4	3.7	45.9
Tubular Glass	4.1	4.1	0.0
Life Science Research	0.1	0.5	-80.0
Total capital expenditure	**16.6**	**14.9**	**11.4**

The Gerresheimer Group's capital expenditure in the first quarter of 2013 was EUR 16.6m (Q1 2012: EUR 14.9m). In Plastic Systems, capital expenditure on infrastructure continued at Pfreimd. Capital expenditure in the Moulded Glass Division primarily related to the purchase of an IS-machine at a German plant and the scheduled general overhaul of a furnace in India. Capital expenditure in the Tubular Glass Division focused on the new production line for prefillable glass syringes RTF®-4.

EMPLOYEES

At February 28, 2013 Gerresheimer employed 11,316 people (November 30, 2012: 10,952). The increase in employees in the Gerresheimer Group and especially in Asia is related to the first time inclusion of the Indian company Triveni with 299 employees.

EMPLOYEES BY REGION (prior year)



At February 28, 2013 the Gerresheimer Group, employed 5,648 people in Europe (including 3,404 in Germany), 3,406 in Americas (including Mexico, Brazil and Argentina) and 2,262 in Asia.

REPORT ON RISKS AND OPPORTUNITIES

Gerresheimer continues to focus on growth in the core segment of pharmaceutical primary packaging and drug delivery devices. Global economic trends, exchange rate factors, rising material and energy prices and uncertainties about the future development of national healthcare systems and customer demand represent risks which may affect the course of business in the long term. We are conscious of these risks and carry out regular reviews.

No risks which could threaten the Gerresheimer Group's existence are currently identifiable. There have not been any material changes to the statements made in the chapter "Opportunities and Risks" of our 2012 Annual Report.

OUTLOOK

The following statements on the Gerresheimer Group's future business performance and the assumptions made in regard to the economic development of the market and industry deemed to be significant in this respect are based on our assessments which we believe are realistic in accordance with the information currently available to us. However, these assessments entail uncertainty and present the unavoidable risk that the developments may not actually occur either in line with the tendency or the degree to which they were forecast.

DEVELOPMENT OF THE ECONOMIC ENVIRONMENT

Global and regional economic development

The assessment of the economic conditions has not changed fundamentally compared with our disclosures in our annual report. Therefore, we refer to the Outlook section in our Annual Report 2012.

MARKET AND BUSINESS OPPORTUNITIES FOR THE GERRESHEIMER GROUP

Prospects for the 2013 financial year

Plastic Systems

As already explained in our Annual Report 2012, we continue to see strong growth opportunities in connection with prescription drugs in plastic pharmaceutical packaging systems. This applies most of all to compounds filled into our drug delivery devices. These devices additionally give pharmaceutical companies a differentiation point in competition for the best drug delivery option. Growth will probably be less robust in the over-the-counter drug market, which we serve with standardized plastic phar-maceutical packaging. From the current perspective, tool development and production orders remain at a high level; this lower revenue margin business generally precedes production orders. The costs of putting new production lines into operation and individual price concessions are likely to hold down margin performance in 2013.

Moulded Glass

Furthermore, we believe that the market for over-the-counter medication may show somewhat less robust growth than in 2012. We could see first trends as confirmation of this development in the first quarter of 2013. As already forecasted, the development of the cosmetics market is subject to uncertainty given the economic environment. We nonetheless expect to increase revenues with glass cosmetics products. Given the general economic environment coupled with the exceptionally high comparative figures for 2011 and 2012, as already forecasted, business growth will tend to lose speed and momentum from the current perspective.

Tubular Glass

In our Tubular Glass Division, given a good order position for RTF®-syringes, we expect an improvement in the adjusted EBITDA margin on the total year basis. Higher quality standards in the form of substantially reduced manufacturing tolerances required changes in RTF®-syringe production and resulted in higher scrap rates in the past financial year. With further stabilization in the production process, we expect lower scrap rates and hence slightly improved profitability in 2013. Prerequisite for this is, however, a stable production process, which has not yet been seen in the first quarter 2013. Furthermore, the start-up costs for the fourth RTF®-syringe line will burden the adjusted EBITDA margin. Revenues from ampoules and vials, which are considered to be among the most efficient pharmaceutical packaging choices made of glass, are likely to continue to benefit from growing demand from industrialized and emerging markets.

Life Science Research

It is more difficult to forecast the prospects for the Life Science Research Division because of its business model; the products are not sold directly but via distributors and lead times for orders are very short. As business performance is closely tied to the development of the US economy, projections are highly uncertain. It is, however, becoming more and more clear, that our customers will elect a more restrictive expenditure policy in 2013 due to bigger austerity measures. For this reason, it is not possible to state for certain whether we will be able to maintain the preceding years' growth rates in 2013. Our target of increasing the Life Science Research Division's adjusted EBIDTA margin to 15% remains unchanged. However, as already communicated, we will probably not yet attain that target in 2013.

Overall Group

The Gerresheimer Group pursues a clear and successful strategy geared toward sustained, profitable growth. For the financial year 2013, we continue to anticipate revenue growth of 5% to 6% at constant exchange rates, even though this forecast seems slightly more conservative now against the background of the strong revenue growth in the first quarter of 2013. We would like to make the adjusted EBITDA margin of around 19.4% more definite for the financial year 2013. Primarily in light of the strong growth prospects, including customer projects in the medical devices business lasting several years, capital expenditure in the financial year 2013 will be on a par with the past financial year, meaning around 9% to 10% of the revenue at constant exchange rates. For 2014 we continue to anticipate solid revenue growth and a return to growth in the adjusted EBITDA margin.

Interim Consolidated Financial Statements (IFRS) December 2012–February 2013

CONSOLIDATED INCOME STATEMENT (IFRS)

for the Period from December 1, 2012 to February 28, 2013

in EUR k	Note	**Dec. 1, 2012– Feb. 28, 2013**	Pro forma[1] Dec. 1, 2011– Feb. 29, 2012
Revenues		296,695	268,809
Cost of sales		-220,949	-193,342
Gross profit		**75,746**	**75,467**
Selling and administrative expenses		-56,100	-54,526
Other operating income		4,318	1,743
Other operating expenses		-2,482	-4,114
Share of profit or loss of associated companies		-5	-333
Results of operations		**21,477**	**18,237**
Finance income		1,930	527
Finance expenses		-8,297	-8,236
Net finance expenses		**-6,367**	**-7,709**
Net income before income taxes		15,110	10,528
Income taxes	(5)	-4,889	-3,309
Net income		**10,221**	**7,219**
Attributable to equity holders of the parent		8,596	5,549
Attributable to non-controlling interests		1,625	1,670
Earnings per share (in EUR)[2]		**0.27**	**0.18**

[1] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.
[2] The basic earnings per share figure stated here also corresponds to the diluted earnings per share as no further shares have been issued.

Notes (1) to (12) are integral part of these interim consolidated financial statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (IFRS)

for the Period from December 1, 2012 to February 28, 2013

in EUR k	Dec. 1, 2012– Feb. 28, 2013	Pro forma[1)] Dec. 1, 2011– Feb. 29, 2012
Net income	**10,221**	**7,219**
Items that may be reclassified subsequently to profit or loss		
Change in the fair value of derivative financial instruments used for hedging	644	-18
Amount reclassified to the income statement	-90	-57
Income taxes	-303	-35
Change in the cash flow hedge reserve recorded in equity	**251**	**-110**
Change in the adjustment from currency translation of foreign subsidiaries	3,573	13,054
Change in the currency translation reserve recorded in equity	**3,573**	**13,054**
Other comprehenisve income	**3,824**	**12,944**
Total result	**14,045**	**20,163**
Attributable to equity holders of the parent	12,964	18,979
Attributable to non-controlling interests	1,081	1,184

1) Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Notes (1) to (12) are integral part of these interim consolidated financial statements.

CONSOLIDATED BALANCE SHEET (IFRS)

as at February 28, 2013

ASSETS

in EUR k	Notes	**Feb. 28, 2013**	Pro forma[1] Nov. 30, 2012
Non-current assets			
Intangible assets		591,458	529,695
Property, plant and equipment		517,422	518,336
Investment property		4,471	4,471
Investments accounted for using the equity method		3,689	3,730
Other financial assets		7,180	7,740
Deferred tax assets		7,226	7,389
		1,131,446	**1,071,361**
Current assets			
Inventories	(7)	200,553	188,957
Trade receivables		187,965	179,439
Income tax receivables		1,895	1,021
Other financial assets		258	5,325
Other receivables		24,281	23,713
Cash and cash equivalents		61,611	86,087
		476,563	**484,542**
Total assets		**1,608,009**	**1,555,903**

[1] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Notes (1) to (12) are integral part of these interim consolidated financial statements.

EQUITY AND LIABILITIES

in EUR k	Notes	Feb. 28, 2013	Pro forma[1)] Nov. 30, 2012
Equity			
Subscribed capital		31,400	31,400
Capital reserve		513,827	513,827
Cash flow hedge reserve		-1,660	-1,933
Currency translation reserve		-3,428	-7,523
Retained earnings		-53,333	-42,473
Equity attributable to equity holders of the parent		**486,806**	**493,298**
Non-controlling interests		64,333	44,909
		551,139	**538,207**
Non-current liabilities			
Deferred tax liabilities		39,748	37,571
Provisions for pensions and similar obligations		175,821	183,739
Other provisions		12,164	11,588
Financial liabilities		437,984	418,925
Other liabilities		3,041	1,709
		668,758	**653,532**
Current liabilities			
Provisions for pensions and similar obligations		20,969	14,926
Other provisions		37,872	43,023
Trade payables		129,305	154,301
Financial liabilities		92,365	44,112
Income tax liabilities		12,106	12,674
Other liabilities		95,495	95,128
		388,112	**364,164**
		1,056,870	**1,017,696**
Total equity and liabilities		**1,608,009**	**1,555,903**

1) Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Notes (1) to (12) are integral part of these interim consolidated financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (IFRS)

for the Period from December 1, 2012 to February 28, 2013

in EUR k	Subscribed capital	Capital reserves	Cash flow hedge reserve	Currency translation reserve	Retained earnings	Equity holders of the parent	Non-controlling interests	**Total equity**
As at December 1, 2011	**31,400**	**513,827**	**-1,972**	**3,140**	**-34,748**	**511,647**	**40,583**	**552,230**
Early adoption of IAS 19 amended	–	–	–	–	-15,667	-15,667	-19	-15,686
As at December 1, 2011 pro forma[1)]	**31,400**	**513,827**	**-1,972**	**3,140**	**-50,415**	**495,980**	**40,564**	**536,544**
Net income pro forma[1)]	–	–	–	–	5,549	5,549	1,670	7,219
Other comprehensive income	–	–	-105	13,535	–	13,430	-486	12,944
Total result	**–**	**–**	**-105**	**13,535**	**5,549**	**18,979**	**1,184**	**20,163**
As at February 29, 2012 pro forma[1)]	**31,400**	**513,827**	**-2,077**	**16,675**	**-44,866**	**514,959**	**41,748**	**556,707**
As at December 1, 2012 pro forma[1)]	**31,400**	**513,827**	**-1,933**	**-7,523**	**-42,473**	**493,298**	**44,909**	**538,207**
Change in the consolidated group	–	–	–	–	–	–	19,456	19,456
Put option					-19,456	-19,456	–	-19,456
Net income	–	–	–	–	8,596	8,596	1,625	10,221
Other comprehensive income	–	–	273	4,095	–	4,368	-544	3,824
Total result	**–**	**–**	**273**	**4,095**	**8,596**	**12,964**	**1,081**	**14,045**
Distribution	–	–	–	–	–	–	-1,113	-1,113
As at February 28, 2013	**31,400**	**513,827**	**-1,660**	**-3,428**	**-53,333**	**486,806**	**64,333**	**551,139**

[1)] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Notes (1) to (12) are integral part of these interim consolidated financial statements.

CONSOLIDATED CASH FLOW STATEMENT (IFRS)

for the Period from December 1, 2012 to February 28, 2013

in EUR k	**Dec. 1, 2012– Feb. 28, 2013**	Pro forma[1] Dec. 1, 2011– Feb. 29, 2012
Net income	10,221	7,219
Income taxes	4,889	3,309
Depreciation of property, plant and equipment	20,236	19,775
Amortization of intangible assets	4,146	4,511
Change in value of equity-accounted investments	5	333
Change in other provisions	-4,215	4,039
Change in provisions for pensions and similar obligations	-2,718	-3,529
Loss/gain on the disposal of non-current assets	203	-520
Net finance expenses	6,367	7,709
Interest paid	-3,284	-2,167
Interest received	287	672
Income taxes paid	-4,307	-3,292
Income taxes received	142	720
Change in inventories	-9,472	-20,043
Change in trade receivables and other assets	415	-378
Change in trade payables and other liabilities	-22,116	-11,729
Other non-cash expenses/income	-717	1,185
Cash flow from operating activities	**82**	**7,814**
Cash received from disposals of non-current assets	169	1,064
Cash paid for investments		
in property, plant and equipment	-16,340	-14,436
in intangible assets	-294	-419
Cash paid in in connection with divestments	1,643	450
Cash paid out for the acquisition of subsidiaries, net of cash received	-52,153	-707
Cash flow from investing activities	**-66,975**	**-14,048**
Distributions to third parties	-1,525	–
Raising of loans	77,754	4,250
Repayment of loans	-33,166	-21,014
Repayment of finance lease liabilities	-479	-866
Cash flow from financing activities	**42,584**	**-17,630**
Changes in cash and cash equivalents	**-24,309**	**-23,864**
Effect of exchange rate changes on cash and cash equivalents	-167	1,145
Cash and cash equivalents at the beginning of the period	86,087	131,432
Cash and cash equivalents at the end of the period	**61,611**	**108,713**

[1] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Notes (1) to (12) are integral part of these interim consolidated financial statements.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

of Gerresheimer AG for the Period from December 1, 2012 to February 28, 2013

(1) General

The Gerresheimer Group based in Duesseldorf, Germany, comprises Gerresheimer AG and its direct and indirect subsidiaries.

The present interim consolidated financial statements were prepared in accordance with the International Financial Reporting Standards (IFRSs) published by the International Accounting Standards Board (IASB) as adopted by the European Union (sec. 315a HGB) ("Handelsgesetzbuch": German Commercial Code) and in accordance with IAS 34 "Interim Financial Reporting". These notes to the interim consolidated financial statements therefore do not contain all the information and details required by IFRS for consolidated financial statements at the end of a financial year, and should be read in conjunction with the consolidated financial statements as at November 30, 2012. The present financial statements have not been audited.

The consolidated income statement was drawn up using the function of expense method and is supplemented by a consolidated statement of comprehenisve income. The same accounting principles generally apply as in the annual consolidated financial statements for 2012.

The first time adoption of the following standards was mandatory:

› IAS 1, Presentation of Financial Statements–Presentation of Items of Other Comprehensive Income
› IAS 12, Income Taxes–Deferred Tax: Recovery of Underlying Assets

The application of the abovementioned standards has not had any material effect on the interim consolidated financial statements.

The first time adoption of the following standard was voluntary:
› IAS 19, Employee Benefits (amended in 2011)

The Gerresheimer Group decided on the early application of IAS 19 (amended in 2011) from December 1, 2012. The first time adoption was carried out retrospectively, i.e. a respective adjustment of the prior periods was made.

The primary effects from the early adoption of IAS 19 (amended in 2011) are as follows:
› Elimination of the so-called corridor approach: as a result of the elimination of the existing accounting options regarding the recognition of actuarial gains and losses, these must now be fully recognized in equity without affecting net income.
› Calculation of the defined benefit cost: the net interest expense from defined benefit pension plans is determined on the basis of a net liability, i.e. the balance of the pension obligation and the fair value of plan assets.
› Past service cost: in the event of future plan amendments, past service costs must be immediately recorded in the income statement.
› Risk sharing: the amended regulation on risk sharing between employees and employers affects both the defined benefit obligation as well as the allocation of the service costs.

The effects on the respective positions of the interim consolidated financial statements are as follows:

CONSOLIDATED INCOME STATEMENT (IFRS)

for the Period from December 1, 2011 to February 29, 2012

in EUR k	Dec. 1, 2011– Feb. 29, 2012	Adjustment	Pro forma Dec. 1, 2011– Feb. 29, 2012
Cost of sales	-194,182	840	-193,342
Gross profit	**74,627**	**840**	**75,467**
Results of operations	**17,397**	**840**	**18,237**
Finance income	674	-147	527
Finance expenses	-8,233	-3	-8,236
Net finance expenses	**-7,559**	**-150**	**-7,709**
Net income before income taxes	9,838	690	10,528
Income taxes	-3,069	-240	-3,309
Net income	**6,769**	**450**	**7,219**
Attributable to equity holders of the parent	5,098	451	5,549
Attributable to non-controlling interests	1,671	-1	1,670
Basic and diluted earnings per share (in EUR)	**0.16**	**0.02**	**0.18**

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (IFRS)

for the Period from December 1, 2011 to February 29, 2012

in EUR k	Dec. 1, 2011– Feb. 29, 2012	Adjustment	Pro forma Dec. 1, 2011– Feb. 29, 2012
Net income	6,769	450	7,219
Other comprehensive income	12,944	–	12,944
Total result	**19,713**	**450**	**20,163**
Attributable to equity holders of the parent	18,528	451	18,979
Attributable to non-controlling interests	1,185	-1	1,184

CONSOLIDATED BALANCE SHEET (IFRS)

as at November 30, 2012

in EUR k	Nov. 30, 2012	Adjustment	Netting	Pro forma Nov. 30, 2012
Other financial assets	9,706	-1,966	–	7,740
Deferred tax assets	7,269	18,601	-18,481	7,389
Total assets	**1,557,749**	**16,635**	**-18,481**	**1,555,903**
Retained earnings	-634	-41,839	–	-42,473
Equity attributable to equity holders of the parent	535,137	-41,839	–	493,298
Non-controlling interests	45,020	-111	–	44,909
Deferred tax liabilities	56,052	–	-18,481	37,571
Provisions for pensions and similar obligations (non-current)	125,154	58,585	–	183,739
Total equity and liabilities	**1,557,749**	**16,635**	**-18,481**	**1,555,903**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (IFRS)

for the Period from December 1, 2011 to February 29, 2012

	Attributable to equity holders of the parent			Attributable to non-controlling interests		
in EUR k	Reported	Adjustment	Pro forma	Reported	Adjustment	Pro forma
As at December 1, 2011	**511,647**	**-15,667**	**495,980**	**40,583**	**-19**	**40,564**
Net income	5,098	451	5,549	1,671	-1	1,670
Other comprehenisve income	13,430	–	13,430	-486	–	-486
Total result	**18,528**	**451**	**18,979**	**1,185**	**-1**	**1,184**
As at February 29, 2012	**530,175**	**-15,216**	**514,959**	**41,768**	**-20**	**41,748**

CONSOLIDATED CASH FLOW STATEMENT (IFRS)

for the Period from December 1, 2011 to February 29, 2012

in EUR k	Dec. 1, 2011– Feb. 29, 2012	Adjustment	Pro forma Dec. 1, 2011– Feb. 29, 2012
Net income	6,769	450	7,219
Income taxes	3,069	240	3,309
Change in provisions for pensions and similar obligations	-2,689	-840	-3,529
Net finance expenses	7,559	150	7,709
Cash flow from operating activities	**7,814**	**–**	**7,814**

RESULTS OF OPERATIONS

for the Period from December 1, 2011 to February 29, 2012

in EUR m	Dec. 1, 2011– Feb. 29, 2012	Adjustment	Pro forma Dec. 1, 2011– Feb. 29, 2012
Adjusted EBITDA			
Plastic Systems	17.5	–	17.5
Moulded Glass	16.4	-0.1	16.3
Tubular Glass	13.2	0.6	13.8
Life Science Research	2.5	–	2.5
Subtotal	**49.6**	**0.5**	**50.1**
Head office/ Consolidation	-5.3	0.3	-5.0
Total adjusted EBITDA	**44.3**	**0.8**	**45.1**

In the following, effects on further restated figures reported in this interim report are explained:

CONSOLIDATED INCOME STATEMENT (IFRS)

for the Period from December 1, 2011 to November 30, 2012

in EUR k	Dec. 1, 2011– Nov. 30, 2012	Adjustment	Pro forma Dec. 1, 2011– Nov. 30, 2012
Cost of sales	-861,629	3,360	-858,269
Gross profit	**357,439**	**3,360**	**360,799**
Results of operations	**128,460**	**3,360**	**131,820**
Finance income	4,044	-587	3,457
Finance expenses	-36,750	12	-36,738
Net finance expenses	**-32,706**	**-575**	**-33,281**
Net income before income taxes	95,754	2,785	98,539
Income taxes	-29,239	-959	-30,198
Net income	**66,515**	**1,826**	**68,341**
Attributable to equity holders of the parent	60,191	1,830	62,021
Attributable to non-controlling interests	6,324	-4	6,320
Basic and diluted earnings per share (in EUR)	**1.92**	**0.06**	**1.98**

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (IFRS)

for the Period from December 1, 2011 to November 30, 2012

in EUR k	Dec. 1, 2011– Nov. 30, 2012	Adjustment	Pro forma Dec. 1, 2011– Nov. 30, 2012
Net income	66,515	1,826	68,341
Other comprehensive income	-9,091	-28,090	-37,181
Total result	**57,424**	**-26,264**	**31,160**
Attributable to equity holders of the parent	49,567	-26,172	23,395
Attributable to non-controlling interests	7,857	-92	7,765

CONSOLIDATED BALANCE SHEET (IFRS)

as at February 29, 2012

in EUR k	Feb. 29, 2012	Adjustment	Netting	Pro forma Feb. 29, 2012
Deferred tax assets	9,284	7,367	-7,367	9,284
Total assets	**1,513,532**	**7,367**	**-7,367**	**1,513,532**
Retained earnings	-29,650	-15,216	–	-44,866
Equity attributable to equity holders of the parent	530,175	-15,216	–	514,959
Non-controlling interests	41,768	-20	–	41,748
Deferred tax liabilities	47,813	240	-7,367	40,686
Provisions for pensions and similar obligations (non-current)	131,868	22,363	–	154,231
Total equity and liabilities	**1,513,532**	**7,367**	**-7,367**	**1,513,532**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (IFRS)

for the Period from December 1, 2011 to November 30, 2012

	Attributable to equity holders of the parent			Attributable to non-controlling interests		
in EUR k	Reported	Adjustment	Pro forma	Reported	Adjustment	Pro forma
As at December 1, 2011	**511,647**	**-15,667**	**495,980**	**40,583**	**-19**	**40,564**
Net income	60,191	1,830	62,021	6,324	-4	6,320
Other comprehensive income	-10,624	-28,002	-38,626	1,533	-88	1,445
Total result	**49,567**	**-26,172**	**23,395**	**7,857**	**-92**	**7,765**
As at November 30, 2012	**535,137**	**-41,839**	**493,298**	**45,020**	**-111**	**44,909**

RESULTS OF OPERATIONS

for the Period from December 1, 2011 to November 30, 2012

in EUR m	Dec. 1, 2011– Nov. 30, 2012	Adjustment	Pro forma Dec. 1, 2011– Nov. 30, 2012
Adjusted EBITDA			
Plastic Systems	92.8	0.1	92.9
Moulded Glass	81.8	-0.2	81.6
Tubular Glass	67.8	2.4	70.2
Life Science Research	13.5	–	13.5
Subtotal	**255.9**	**2.3**	**258.2**
Head office/Consolidation	-19.4	1.1	-18.3
Total adjusted EBITDA	**236.5**	**3.4**	**239.9**

Furthermore, in preparing the interim consolidated financial statements in accordance with prevailing accounting principles, estimates, assumptions and discretionary decisions are made which have an effect on the recognition and valuation of assets and liabilities, the disclosure of contingent liabilities and assets as at the balance sheet date as well as on the amount of income and expenses in the reporting period. Although the estimates are made to the best of management's knowledge of current events and transactions, actual future results may differ from the estimates.

The interim consolidated financial statements are in euro, the functional currency of the parent company. Conversion of the major currencies in the Group was based on the following exchange rates:

	Closing rate		Average rate	
1 EUR	Feb. 28, 2013	Feb. 29, 2012	Dec. 1, 2012– Feb. 28, 2013	Dec. 1, 2011– Feb. 29, 2012
ARS	6.6187	5.8569	6.5358	5.7191
BRL	2.5871	2.2872	2.6771	2.3566
CHF	1.2209	1.2051	1.2171	1.2130
CNY	8.1720	8.4608	8.2265	8.3721
CZK	25.6370	24.8430	25.4145	25.2848
DKK	7.4560	7.4356	7.4594	7.4354
GBP	0.8630	0.8439	0.8370	0.8425
INR	71.3860	65.8100	74.5914	67.4438
MXN	16.7554	17.1949	16.9690	17.6201
PLN	4.1515	4.1212	4.1330	4.3279
SEK	8.4475	8.8088	8.5760	8.9409
USD	1.3129	1.3443	1.3212	1.3244

The consolidated financial statements of Gerresheimer AG as at November 30, 2012 are published in German in the Federal Law Gazette (Bundesanzeiger) and on the Internet at www.gerresheimer.com.

(2) Seasonal Effects on Business Activity

The business is subject to seasonal influences, as revenues and cash flows in Europe and North America are usually lowest in the holiday period in December/January and during the summer months.

3) Changes in the Group of Consolidated Companies

On December 17, 2012 Gerresheimer signed the sale and purchase agreement for a 75% stake in the Indian company Triveni Polymers Private Ltd., New Delhi (Triveni). The transaction was completed on December 20, 2012 and since this point in time the company has been included in the consolidated financial statements of Gerresheimer AG. In addition, from April 1, 2016, Gerresheimer has the possibility to purchase the remaining 25% stake by exercising its option to buy (call option). From this date onwards the seller can tender the remaining 25% stake to Gerresheimer by exercising its option to sell (put option).

The preliminary acquisition cost for the majority shareholding amounted to INR 3.8 bn (around EUR 52.2m). Acquisition related costs including those incurred in the prior financial year amount to EUR 0.5m, of which EUR 0.2m are included under the one-off expenses in the position other operating expenses, which are in part compensated by one-off income of EUR 0.1m which are included under other operating income in the current financial year.

Triveni is a producer of pharmaceutical plastic packaging in India. This acquisition is a further ideal step towards enhancing the position of the Gerresheimer Group in the emerging markets. Triveni is a leading and fast growing company with excellent profitability that provides high value for Gerresheimer. In the financial year 2011/2012 (April 1, 2011 to March 31, 2012) the company generated revenues of around INR 1.3 bn (around EUR 20m) and employed more than 300 people.

The preliminary fair values identified at the acquisition date of the assets, liabilities, and contingent liabilities acquired are presented as follows:

in EUR m	
ASSETS	
Non-current assets	
Intangible assets	62.5
Property, plant and equipment	3.9
	66.4
Current assets	
Inventories	2.4
Receivables and other assets	5.8
Cash and cash equivalents	0.1
	8.3
	74.7
EQUITY AND LIABILITIES	
Non-controlling interests	**19.5**
Deferred tax liabilities	**0.1**
Liabilities	
Financial liabilities	2.5
Other liabilities	0.4
	2.9
Purchase price	52.2
	74.7

Goodwill of EUR 62.5m resulting from the preliminary purchase price allocation is currently being shown. The final fair values including intangible assets and contingent liabilities, which have to be reported separately, are currently being determined. According to IFRS, adjustments to the provisional reporting of the merger must be made within twelve months from the acquisition date.

The option of selling the remaining shares granted to the non-controlling interests has been accounted for as a put option within Group equity with a value of EUR 19.5m and is included in non-current financial liabilities in the consolidated balance sheet.

In the first weeks of inclusion in the Group, Triveni generated revenue of EUR 4.2m, EBITDA of EUR 1.5m and net income after income taxes of EUR 1.0m. If Triveni had been included in the consolidated financial statements since the beginning of the financial year 2012/2013, Triveni would have contributed EUR 5.3m to the Group revenue, EUR 1.6m to EBITDA and EUR 1.0m to net income after income taxes.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(4) Amortization of Fair Value Adjustments

The following table shows the amortization of fair value adjustments made following the acquisitions of Gerresheimer Group GmbH in December 2004, Gerresheimer Vaerloese (formerly Dudek Plast Group) at the end of December 2005, the Gerresheimer Regensburg Group (formerly Wilden Group) in early January 2007, the pharmaceutical glass business of Comar Inc., US, in March 2007, the newly formed joint venture Kimble Chase in July 2007, as well as Gerresheimer Zaragoza and Gerresheimer Plasticos Sao Paulo in January 2008, Vedat Tampas Hermeticas Ltda. (merged with Gerresheimer Plasticos Sao Paulo) in March 2011 and Neutral Glass in April 2012:

in EUR m	Fair value adjustments Carrying value as at Feb. 28, 2013	**Fair value adjustments Amortization Q1 2013**	Fair value adjustments Amortization Q1 2012
Customer base	43.0	2.8	3.3
Orders on hand	–	–	0.1
Brand names	35.9	–	–
Technologies	5.8	0.4	0.4
Process know-how	0.1	–	–
Land	4.9	–	–
Buildings	9.3	0.1	0.1
Machinery	8.4	0.5	0.6
	107.4	**3.8**	**4.5**

The amortization of the fair value adjustments is disclosed in the functional areas. Of the total EUR 3.8m fair value amortization (comparative prior year period: EUR 4.5m), EUR 1.0m (comparative prior year period: EUR 1.1m) relate to cost of sales and EUR 2.8m (comparative prior year period: EUR 3.4m) to selling expenses.

The brand names contained in the above table were identified as intangible assets with an indefinite useful economic life. Brand names are therefore not subject to straight-line amortization, instead, in accordance with IFRS 3, “Business Combinations”, IAS 36, “Impairment of Assets” and IAS 38, “Intangible Assets”, they are tested for impairment at least once a year.

(5) Income Taxes

The main components of income tax reported in the consolidated income statement are as follows:

in EUR k	Q1 2013	Q1 2012
Current income taxes	-2,997	-2,268
Deferred income taxes	-1,892	-1,041
	-4,889	**-3,309**

The Group's current tax ratio is 32.4% (comparative prior year quarter: 31.4%).

(6) Distributions to Third Parties

In the first quarter 2013 distributions to non-controlling interests of EUR 1.1m were made to Chase Scientific Glass Inc., USA, which has a 49% shareholding in the joint venture Kimble Chase Life Science and Research Products LLC.

In the financial year 2012 a dividend to the non-controlling interests of Gerresheimer Shuangfeng Pharnaceutical Glass (Danyang) Co. Ltd., China of EUR 1.1m was agreed. At November 30, 2012 EUR 0.7m had been paid. The outstanding balances were included in liabilities at the balance sheet date. In the first quarter 2013 further EUR 0.4m were paid.

(7) Inventories

in EUR k	Feb. 28, 2013	Nov. 30, 2012
Raw materials, consumables and supplies	51,751	45,100
Work in progress	21,513	27,832
Finished goods and merchandise	110,965	103,618
Advance payments on inventories	16,324	12,407
Inventories	**200,553**	**188,957**

Expenses arising from write-downs on inventory amount to EUR 1.6m in the current financial year. If the reasons which led to a write-down cease to exist, write-downs previously set up are reversed. Such reversals amount to EUR 1.9m in the financial year.

(8) Financial Liabilities

The Management Board of Gerresheimer AG decided to commence the refinancing of the syndicated loan and the high-yield bond ahead of schedule at the beginning of the year 2011. In connection with the refinancing a new syndicated loan agreement with a five-year term to maturity which comprises a long-term loan of originally EUR 150m (fully drawn in USD) and a revolving credit facility of EUR 250m was signed on March 9, 2011. At the balance sheet date EUR 45m of the revolving credit facility had been drawn.

In April 2011 the bond of EUR 126.0m issued in Luxembourg which was due for repayment in the year 2015, was replaced ahead of schedule. A new bond of EUR 300.0m was issued on Mai 19, 2011 and is due for repayment in the year 2018. This bond is also issued in Luxembourg. In order to finance the earlier replacement Gerresheimer signed an agreement on credit facilities in March 2011 amounting to EUR 200.0m with a maturity to March 2012 and an option of renewal for six months. The funds received from the new bond were used to repay this credit facility.

(9) Other Financial Obligations

Obligations from rental and operating lease agreements as well as from capital expenditure commitments and guarantees amounted to EUR 73.9m at February 28, 2013 and have decreased by EUR 4.8m compared to November 30, 2012.

(10) Segment Reporting

The Gerresheimer Group comprises the four divisions of Plastic Systems, Moulded Glass, Tubular Glass and Life Science Research. The segment reporting is in line with the Company's strategic focus and shows the following picture in accordance with IFRS 8:

By division in EUR m		Plastic Systems	Moulded Glass	Tubular Glass	Life Science Research	Head office/ Consolida-tion	Group
Segment revenues	Q1 13	110.1	90.8	77.8	21.5	–	300.2
	Q1 12	91.6	84.0	73.7	23.0	–	272.3
Thereof intra group revenues	Q1 13	–	-0.1	-3.4	–	–	-3.5
	Q1 12	-0.1	–	-3.4	–	–	-3.5
Revenues third parties	Q1 13	110.1	90.7	74.4	21.5	–	296.7
	Q1 12	91.5	84.0	70.3	23.0	–	268.8
Adjusted EBITDA	Q1 13	18.5	16.3	14.2	2.5	-5.5	46.0
	Q1 12[1)]	17.5	16.3	13.8	2.5	-5.0	45.1
Depreciation and amortization	Q1 13	-6.3	-7.5	-6.3	-0.4	-0.1	-20.6
	Q1 12	-5.6	-7.1	-6.2	-0.8	-0.1	-19.8
Adjusted EBITA	Q1 13	12.2	8.8	7.9	2.1	-5.6	25.4
	Q1 12[1)]	11.9	9.2	7.6	1.7	-5.1	25.3
Restructuring/one-off expenses and income	Q1 13	–	–	–	–	–	-0.1
	Q1 12	–	–	–	–	–	-2.6
Amortization of fair value adjustments	Q1 13	–	–	–	–	–	-3.8
	Q1 12	–	–	–	–	–	-4.5
Results of operations	Q1 13	–	–	–	–	–	21.5
	Q1 12[1)]	–	–	–	–	–	18.2
Net finance expenses	Q1 13	–	–	–	–	–	-6.4
	Q1 12[1)]	–	–	–	–	–	-7.7
Net working capital	Q1 13	58.2	65.7	71.2	27.8	-1.6	221.3
	Q1 12	49.5	56.4	64.0	27.2	-0.6	196.5
Operating cash flow	Q1 13	1.8	2.7	-7.2	0.8	-7.9	-9.8
	Q1 12[1)]	-0.6	14.5	-0.5	0.7	-6.3	7.8
Capital expenditure	Q1 13	7.0	5.4	4.1	0.1	–	16.6
	Q1 12	6.6	3.7	4.1	0.5	–	14.9

[1)] Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012. A detailed explanation of the effects from the restatement can be found in the notes to this interim report.

Transfer prices between the divisions are based on customary market terms on an arm's length basis.

(11) Related Party Disclosures (IAS 24)

Within the scope of our operations, we conduct business with legal and individual persons that are able to influence Gerresheimer AG or their subsidiaries or over which Gerresheimer AG or its subsidiaries have control or on which they exert a significant influence.

These include companies that have relations to members of the Supervisory Board of Gerresheimer AG, non consolidated companies and associated companies as well as the members of the Supervisory Board and Management Board of Gerresheimer AG.

Business with companies which have relations to one member of the Supervisory Board of Gerresheimer AG relate to the company Vetter Pharma Fertigung GmbH & Co. KG, Ravensburg, Germany, and mainly relate to trade relations which are always at arm's length prices and conditions and totaled EUR 0.9m in the in the first quarter 2013 (prior year: EUR 1.5m). At the balance sheet date, trade receivables amounted to EUR 0.4m (prior year: EUR 0.4m).

Business with associated companies also mainly relates to trade relations at arm's length prices and conditions and totaled EUR 0.3m in the first quarter 2013 (prior year: EUR 0.6m). At the balance sheet date, trade receivables amounted to EUR 0.8m (prior year: EUR 1.5m) and trade payables to EUR 0.2m (prior year: EUR 0.6m).

(12) Events after the Balance Sheet Date

In connection with a tax audit carried out for one of our companies in Brazil, a claim has been reported to us. According to this, uncertainty exists as to whether the acquisition structure at the time of the purchase of the company Allplas Embalagens Ltda., Sao Paulo, will be accepted for tax purposes. The final assessment of the issues is pending. Should the assessment prove to be true, this would primarily result in the fact that the tax advantages from using the Brazilian purchasing company would not be accepted. These tax advantages resulted from the amortization of the goodwill arising from the merger of these two companies. From today's perspective, the expense on group level would come to a medium, single digit million euro amount. In line with our internal guidelines we would adjust this amount in our adjusted net income calculation.

There were no further subsequent events after February 28, 2013 which had a significant effect on the net assets, financial position or results of operations of the Gerresheimer Group.

The interim consolidated financial statements were approved on April 9, 2013 after discussion with the Audit Committee and the Supervisory Board.

Financial Calendar

April 10, 2013	Interim Report 1st Quarter 2013
April 18, 2013	Annual General Meeting 2013
July 10, 2013	Interim Report 2nd Quarter 2013
October 2, 2013	Interim Report 3rd Quarter 2013

Imprint

Publisher
Gerresheimer AG
Benrather Strasse 18-20
40213 Duesseldorf
Germany
Tel +49 211 6181-00
Fax +49 211 6181-295
E-mail info@gerresheimer.com
www.gerresheimer.com

Concept and Layout
Kirchhoff Consult AG, Hamburg, Germany

Text
Gerresheimer AG, Duesseldorf, Germany

Note to the Interim Report
This Interim Report is the English translation of the original German version; in case of deviations between these two, the German version prevails.

Note regarding the rounding of figures
Due to the commercial rounding of figures and percentages, small deviations may occur.

Disclaimer
This Interim Report contains certain future-oriented statements. Future-oriented statements include all statements which do not relate to historical facts and events and contain future-oriented expressions such as "believe", "estimate", "assume", "expect", "forecast", "intend", "could" or "should" or expressions of a similar kind. Such future-oriented statements are subject to risks and uncertainties since they relate to future events and are based on the Company's current assumptions, which may not in the future take place or be fulfilled as expected. The Company points out that such future-oriented statements provide no guarantee for the future and that actual events including the financial position and profitability of the Gerresheimer Group and developments in the economic and regulatory fundamentals may vary substantially (particularly on the down side) from those explicitly or implicitly assumed or described in these statements. Even if the actual results for the Gerresheimer Group, including its financial position and profitability and the economic and regulatory fundamentals, are in accordance with such future-oriented statements in this Interim Report, no guarantee can be given that this will continue to be the case in the future.

Gerresheimer AG

Benrather Strasse 18-20
40213 Duesseldorf
Germany
Phone +49 211 61 81 - 00
Fax +49 211 61 81 - 295
E-mail info@gerresheimer.com
www.gerresheimer.com